We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+12.44%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.23B
AUM Growth
-$53.5M
(-4.2%)
Cap. Flow
-$116M
Cap. Flow
% of AUM
-9.36%
Top 10 Holdings %
Top 10 Hldgs %
73.9%
Holding
25
New
1
Increased
3
Reduced
7
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xenon Pharmaceuticals
XENE
|
+$22.4M |
| 2 |
Salesforce
CRM
|
+$13.1M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$5.74M |
| 4 |
BBOT
BridgeBio Oncology
BBOT
|
+$2.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZBIO
Zenas BioPharma
ZBIO
|
+$52.6M |
| 2 |
Insmed
INSM
|
+$34.8M |
| 3 |
ASML
ASML
|
+$26M |
| 4 |
VALN
Valneva
VALN
|
+$12.2M |
| 5 |
Viridian Therapeutics
VRDN
|
+$11.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.46% |
| 2 | Technology | 16.25% |
| 3 | Financials | 11.46% |
| 4 | Consumer Discretionary | 2.62% |
| 5 | Industrials | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$4.39B
| $169M | 13.65% |
5,350,000
| – | – |
|
2
Brookfield
BN
$102B
| $141M | 11.46% |
3,496,245
| – | – |
|
|
3
ASML
ASML
$675B
| $125M | 10.16% |
94,946
-19,000
| -17% | -$26M |
|
|
4
Mirum Pharmaceuticals
MIRM
$6.89B
| $122M | 9.92% |
1,325,000
+60,972
| +5% | +$5.74M |
|
|
MPLT
5
MapLight Therapeutics
MPLT
$1.66B
| $74.9M | 6.07% |
3,686,622
| – | – |
|
|
6
Salesforce
CRM
$134B
| $73.4M | 5.95% |
393,187
+63,000
| +19% | +$13.1M |
|
7
Crinetics Pharmaceuticals
CRNX
$8.86B
| $56.3M | 4.56% |
1,550,000
-75,000
| -5% | -$3.35M |
|
8
Enliven Therapeutics
ELVN
$3.78B
| $50.2M | 4.07% |
1,280,000
-200,000
| -14% | -$5.54M |
|
9
Vaxcyte
PCVX
$7.89B
| $50M | 4.05% |
860,000
-56,160
| -6% | -$3.05M |
|
10
Pharvaris
PHVS
$2.39B
| $49.4M | 4.01% |
1,750,000
| – | – |
|
11
ArriVent BioPharma
AVBP
$1.48B
| $44.8M | 3.63% |
1,942,142
| – | – |
|
|
12
Viridian Therapeutics
VRDN
$2.13B
| $39.1M | 3.17% |
2,000,000
-380,000
| -16% | -$11.3M |
|
13
Celldex Therapeutics
CLDX
$2.77B
| $38.1M | 3.08% |
1,200,000
| – | – |
|
14
Apogee Therapeutics
APGE
$10.2B
| $37.9M | 3.07% |
450,000
-120,000
| -21% | -$8.71M |
|
15
BioMarin Pharmaceuticals
BMRN
$11.5B
| $37.3M | 3.02% |
660,000
| – | – |
|
16
4D Molecular Therapeutics
FDMT
$526M
| $34M | 2.75% |
3,650,737
| – | – |
|
17
Alibaba
BABA
$269B
| $32.3M | 2.62% |
257,327
| – | – |
|
|
18
Xenon Pharmaceuticals
XENE
$6.32B
| $28.2M | 2.29% |
+485,438
| New | +$22.4M |
|
|
BBOT
19
BridgeBio Oncology
BBOT
$707M
| $19.6M | 1.59% |
2,185,923
+224,606
| +11% | +$2.41M |
|
|
VALN
20
Valneva
VALN
$488M
| $6.61M | 0.54% |
1,057,421
-1,247,579
| -54% | -$12.2M |
|
21
LanzaTech
LNZA
$61.3M
| $2.53M | 0.21% |
158,148
| – | – |
|
22
Marqeta
MQ
$1.8B
| $1.8M | 0.15% |
110,390
| – | – |
|
|
23
Insmed
INSM
$23.2B
| – | – |
-200,000
| Closed | -$34.8M |
|
|
IOBT
24
DELISTED
IO Biotech
IOBT
| – | – |
-2,512,453
| Closed | -$1.53M |
|
|
ZBIO
25
Zenas BioPharma
ZBIO
$1.92B
| – | – |
-1,450,000
| Closed | -$52.6M |
|
Similar funds
HCA
GX
MP
FLII
CA
IC
WTA
CCA
Novo Holdings A/S's Q1 2026 Portfolio in Review
As of Q1 2026, Novo Holdings A/S held 25 positions worth $1.23B, down 4.2% from $1.29B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Novo Holdings A/S withdrew a net $116M in Q1 2026, closing 3 positions and reducing 7 holdings. Its most notable exit was Zenas BioPharma, an estimated $52.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 68% a quarter earlier, followed by Technology and Financials.
Against the trend, Novo Holdings A/S opened a new position in Xenon Pharmaceuticals worth $28.2M.
- Novo Holdings A/S's largest Q1 2026 buy was Xenon Pharmaceuticals: 485,438 shares worth $28.2M.
- Novo Holdings A/S added most to Salesforce in Q1 2026, an estimated $13.1M increase.
- Novo Holdings A/S's biggest Q1 2026 reduction was ASML, cutting an estimated $26M.
- Novo Holdings A/S fully exited Zenas BioPharma in Q1 2026, selling an estimated $52.6M.
- Novo Holdings A/S's ten largest holdings make up 74% of its $1.23B portfolio in Q1 2026.
- Novo Holdings A/S opened 1 new position and closed 3 in Q1 2026.
- Novo Holdings A/S's portfolio value fell 4.2% quarter-over-quarter to $1.23B.
Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.